However, de novo and acquired resistance appear in all cases of metastatic breast cancer and in approximately 25% of ER positive breast cancer patients, limiting the efficiency of the treatment used to target the estrogen receptor [162,166]. The gene discussed is ESR1; the disease is breast cancer.